Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boundless Bio
Biotech
Serapha takes flight with $230M, gene-editing prospect from China
The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics.
Eric Sagonowsky
Jun 23, 2026 1:55pm
Boundless scraps combo treatment of 2 unimpressive cancer drugs
Jan 20, 2026 9:00am
Boundless Bio lays off 33% of staff as lead program stumbles
May 27, 2025 8:40am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Boundless drops clinical-stage cancer drug, shakes up C-suite
Dec 13, 2024 7:30am
Drug shrinks tumors in mice by targeting extrachromosomal DNA
Nov 6, 2024 12:50pm
